Papers/PMID:37218346
Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.
The clinical respiratory journal2023The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
montelukast — increases forced expiratory volume in one second (FEV1)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The random‐effects meta‐analysis demonstrated that the FEV1 was improved by montelukast adjuvant therapy with a statistical difference (SMD = 1.15, 95% CI [0.53, 1.77], P < 0.01).”
Quoted verbatim from Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults aged 18 years or older with cough variant asthma; seven RCTs pooled, montelukast added to inhaled corticosteroid plus long-acting beta agonist versus the same inhaled corticosteroid plus long-acting beta agonist alone (background therapy in both arms); high heterogeneity
Effect 1.15 standardised mean difference, 95% CI 0.53 to 1.77
Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.2023PMID:37218346Permalink